Hawaii Pacific Neuroscience
Hawaii Pacific Neuroscience
Honolulu, Hawaii, United States20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-09 | NCT07177352 | |
| An Open-label Study of XEN1101 in Epilepsy | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Tonic-Clonic Seizures, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Enrolling by invitation | Phase 3 | 2026-10-08 | NCT05718817 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 3 | 2026-10-06 | NCT07174310 | |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-06 | NCT03887455 | |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06132893 | |
| Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | Lewy Body Dementia Psychosis | Recruiting | Phase 3 | 2026-09-29 | NCT07095465 | |
| Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | Lewy Body Dementia Psychosis | Recruiting | Phase 2 | 2026-09-29 | NCT07029581 | |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-09-25 | NCT07169578 | |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Active, not recruiting | Phase 3 | 2026-09-22 | NCT06700343 | |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | CNS demyelinating autoimmune disease, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, acute stress disorder, adjustment disorder, amyotrophic lateral sclerosis, anxiety disorder, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, demyelinating disease, depressive disorder, idiopathic pulmonary fibrosis, immune system disorder, interstitial lung disease, lung disorder, metabolic disease, motor neuron disorder, multiple sclerosis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, psychiatric disorder, pulmonary fibrosis, respiratory system disorder, spinal cord disorder | Recruiting | Phase 2 | 2026-09-15 | NCT07002034 | |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-09-11 | NCT07501702 | |
| Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation | Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, brain disorder, central nervous system disorder, dentatorubral-pallidoluysian atrophy, epilepsy, nervous system disorder, progressive myoclonus epilepsy | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT07084311 | |
| A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age | Alzheimer's Disease Dementia; Mild Cognitive Impairment Due to Alzheimer's Disease | Active, not recruiting | Phase 2 | 2026-06-30 | NCT05399888 | |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-05-18 | NCT06709014 | |
| Long-term Safety and Tolerability of BHV-7000 | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Enrolling by invitation | Phase 2 | 2026-05-01 | NCT06443463 | |
| A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | New Onset Generalized Myasthenia Gravis (gMG) | Recruiting | Phase 4 | 2026-03-10 | NCT06909214 | |
| A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Not stated | 2025-11-21 | NCT06538064 | |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, primary dysautonomia, vascular disorder | Active, not recruiting | Phase 3 | 2025-09-05 | NCT05696717 | |
| Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 3 | 2025-05-21 | NCT04006210 | |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder | Active, not recruiting | Phase 2 | 2024-09-24 | NCT03796962 |